Despite the initial negative impact of the COVID-19 pandemic, the European aesthetic injectable market will expand through 2032. Players in this market will help to support growth through new advancements and differentiated products; the emergence of Asian players with low-cost offerings will also expand the availability of products and make them more affordable for patients. Demand for aesthetic injectables will also be spurred by the rising awareness and acceptability of these procedures, as well as a growing patient pool, including nontraditional patient groups such as men and younger individuals.
This Medtech 360 Report provides comprehensive data and analysis on the state of the market for aesthetic injectables in Europe from 2019 through 2032.
New advancements in treatments and products entering the European market will support sales growth.
What new products are entering the market, and how will companies promote adoption of these products?
How do the new products compare to existing ones in the market, and how will they compete against them?
What are the factors that can make a product successful in the aesthetic injectable market?
Despite increasing competitive pressures, large MNCs will continue to dominate the market.
What strategies are established competitors using to maintain their market share?
What are areas that these companies are focusing on going forward?
How will the entrance of newer competitors with low-cost products affect competitive dynamics?
Strategic acquisitions and partnerships help manufacturers expand their product portfolios and customer bases.
What are the notable acquisitions and partnerships that have occurred in this market?
What competitive advantages have these transactions provided to the companies involved?